Atrium Therapeutics posts investor presentation on precision RNA medicines for cardiac disease

Reuters2026/08/13 21:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Atrium Therapeutics highlighted ATR1072, an RNA-targeting program for PRKAG2 syndrome, a genetic cardiomyopathy linked to arrhythmias and cardiomyopathy.
Initial prevalence estimate of 1,000-2,000 PRKAG2 syndrome patients described as conservative, based on published literature.
Early lab outreach identified close to 2,000 individuals with a PRKAG2 mutation from a subset of engaged genetic-testing providers.
Preclinical data showed PRKAG2 mRNA reduction at day 28 in a mouse model, with improvements in diastolic function measures at 24 weeks.
Monkey studies cited target knockdown in heart tissue, with 9-month repeat-dose toxicity study showing no dose-limiting toxicity at highest dose tested.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Atrium Therapeutics Inc. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Atrium Therapeutics posts investor presentation on precision RNA medicines for cardiac disease

You may also like

Crypto prices